We dont have long-term safety data
doi: 10.3389/fphar.2025.1737199 Received 01 November 2025 Revised 21 December 2025 Accepted 29 December 2025 Published 15 January 2026 Volume 16 - 2025 Edited by Dawei Chen, University of Kiel, Germany Reviewed by Eveljn Scarian, University of Pavia, Italy Hong Cheng, Yangzhou University, China Updates Copyright 2026 Knudsen, Tadje, Coggins and Venketaraman
For example, a patient might use subcutaneous injection during active treatment cycles for systemic benefits while applying topical GHK-Cu to the face and neck daily for skin-specific results
71 A novel therapeutic target for MDD is transforming growth factor 1 (TGF-1), the expression of which is controlled by antidepressants
While the September actions were a broad brushstroke against misleading direct-to-consumer ads, this most recent move drills down into the structural ambiguity of the telehealth model